Accepted Manuscript



Volitional limbic neuromodulation has a multifaceted clinical benefit in Fibromyalgia patients

Noam Goldway, Jacob Ablin, Omer Lubin, Yoav Zamir, Jackob Nimrod Keynan, Ayelet Or-Borichev, Marc Cavazza, Fred Charles, Nathan Intrator, Silviu Brill, Eti Ben-Simon, Haggai Sharon, Talma Hendler

PII: S1053-8119(18)32071-8

DOI: https://doi.org/10.1016/j.neuroimage.2018.11.001

Reference: YNIMG 15406

To appear in: *NeuroImage*

Received Date: 18 June 2018

Revised Date: 3 October 2018

Accepted Date: 1 November 2018

Please cite this article as: Goldway, N., Ablin, J., Lubin, O., Zamir, Y., Keynan, J.N., Or-Borichev, A., Cavazza, M., Charles, F., Intrator, N., Brill, S., Ben-Simon, E., Sharon, H., Hendler, T., Volitional limbic neuromodulation has a multifaceted clinical benefit in Fibromyalgia patients, *NeuroImage* (2018), doi: https://doi.org/10.1016/j.neuroimage.2018.11.001.



Volitional Limbic Neuromodulation Has a Multifaceted Clinical Benefit in Fibromyalgia Patients.

Noam Goldway 1,2

Jacob Ablin 3, 5

Omer Lubin 1

Yoav Zamir 1,2

Jackob Nimrod Keynan 1,4

Ayelet Or-Borichev 1,3

Marc Cavazza 8

Fred Charles 9

Nathan Intrator 2,7

Silviu Brill 3,6

Eti Ben-Simon 1

Haggai Sharon* 1,3,6,10

Talma Hendler* 1,2,3,4

* These authors contributed equally to this work

1 Sagol Brain Institute, Wohl Institute for Advanced Imaging, Tel-Aviv Sourasky Medical Centre, Tel-Aviv, Israel

2 Sagol School of Neuroscience, Tel Aviv University, Tel-Aviv, Israel

3 Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

4 School of Psychological Sciences, Tel Aviv University, Tel-Aviv, Israel

5 Department of Internal Medicine, Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel.

6 Institute of Pain Medicine, Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel

7 Blavatnik School of Computer Science, Tel Aviv University, Tel-Aviv, Israel

8 Department of Computing and Information Systems, University of Greenwich, London, UK

9 Faculty of Science and Technology, Bournemouth University, Department of Creative Technology, Poole, UK

10 Pain Management & Neuromodulation Centre, Guy’s & St Thomas' NHS Foundation Trust, London, UK

Corresponding Author:
Noam Goldway
noamgoldway@gmail.com
+972547618085
6 Weizmann St. Tel Aviv 64239, Israel.

Running Title: Limbic Neuromodulation for Fibromyalgia

Abstract

Volitional neural modulation using neurofeedback has been indicated as a potential treatment for chronic conditions that involve peripheral and central neural dysregulation. Here we utilized neurofeedback in patients suffering from Fibromyalgia - a chronic pain syndrome that involves sleep disturbance and emotion dysregulation. These ancillary symptoms, which have an amplification effect on pain, are known to be mediated by heightened limbic activity. In order to reliably probe limbic activity in a scalable manner fit for EEG-neurofeedback training, we utilized an Electrical Finger Print (EFP) model of amygdala-BOLD signal (termed Amyg-EFP), that has been successfully validated in our lab in the context of volitional neuromodulation.

We anticipated that Amyg-EFP-neurofeedback training aimed at limbic down modulation should improve chronic pain in patients suffering from Fibromyalgia, by balancing disturbed indices for sleep and affect. We further expected that improved clinical status would correspond to successful training as indicated by improved down modulation of the Amygdala-EFP signal.

Thirty-Four Fibromyalgia patients (31F; age 35.6±11.82) participated in a randomized placebo-controlled trial with biweekly Amyg-EFP-neurofeedback sessions and placebo of sham neurofeedback (n=9) for a total duration of five consecutive weeks. Following training, participants in the Real-neurofeedback group were divided into good (n=13) or poor (n=12) modulators according to their success in the neurofeedback training. Before and after treatment, self-reports on pain, depression, anxiety, fatigue and sleep quality were obtained, as well as objective sleep Indices. Long-term clinical follow-up was made available, within up to three years of the neurofeedback training completion.

REM latency and objective sleep quality index were robustly improved following the treatment course only in the **Real**-neurofeedback **group** (both time*group $p<0.05$) and to a greater extent among good modulators (both time*sub-group $p<0.05$). In contrast, self-report measures did not reveal a treatment-specific response at the end of the treatment. However, the follow-up assessment revealed a delayed improvement

in chronic pain and subjective sleep experience, evident only in the Real-neurofeedback group (both time*group $p<0.05$). Moderation analysis showed that the enduring clinical effects on pain evident in the follow-up assessment were predicted by the immediate improvements following training in objective sleep and subjective affect measures.

Our findings suggest that Amyg-EFP- neurofeedback that specifically targets limbic activity down modulation offers a successful principled approach for volitional EEG based neuromodulation training in Fibromyalgia patients. Importantly, it seems that via its immediate sleep improving effect, the neurofeedback training induced a delayed reduction in the target subjective symptom of chronic pain, far and beyond the immediate placebo effect. This indirect approach to chronic pain management reflects the necessary link between somatic and affective dysregulation that can be successfully targeted using neurofeedback.

Highlights

- Fibromyalgia patients were trained in limbic neuromodulation
- After training, only **Real-NF group** showed improvement in objective sleep measures
- Follow-up revealed group specific improvement in pain and subjective sleep
- Pain alleviation was moderated by initial improvement in objective sleep and affect
- fMRI driven EEG-NF can serve as a novel approach to treat Fibromyalgia

Registration:
Title: Neurofeedback for Fibromyalgia
ClinicalTrials.gov Identifier: NCT02146495
URL: https://clinicaltrials.gov/ct2/show/NCT02146495

Keywords: Amygdala, Neurofeedback, Fibromyalgia, Chronic Pain, Sleep Disorders, Allostatic Load

Abbreviations: ACR: American College of Rheumatology, Amyg: EFP- Amygdala-Electrical Fingerprint.

1. Introduction

Volitional neuromodulation, known as neurofeedback (NF), allows individuals to exert control over neural activity by bridging between mental states and neural signal modulation (Sitaram et al., 2017). Such bridging may be necessary to preserve somatic-affective homeostasis; maintaining stability of the internal bodily environment and related subjective experience in response to environmental challenges (Barrett and Simmons, 2015).

Chronic somatic disorders involve impaired homeostatic regulation that is mediated by disturbed neural function (Di Lernia et al., 2016a; Elman and Borsook, 2016; Smallwood et al., 2013). **It has been suggested that** NF can be used to modulate neural probes supporting homeostatic regulation, and may therefore be particularly suitable for treating somatic-affective homeostasis related disorders such as insomnia and chronic pain (Arns and Kenemans, 2014; deCharms et al., 2005). However it remains unclear to what extent the NF effects demonstrated in such disorders are mediated by improved homeostasis, as opposed to non-specific, placebo-like processes (Thibault et al., 2016).

Fibromyalgia is a highly prevalent and difficult to treat chronic pain syndrome characterized by widespread pain, intimately related to maladaptive homeostatic processes of sleep and emotion regulation (Choy, 2015; Hamilton et al., 2008; Hassett et al., 2008 Häuser et al., 2015). The pain chronicity in Fibromyalgia was suggested to be a multistep process that involves the breakdown of several control mechanisms, mainly mood regulation and sleep quality (Choy, 2015). In accordance, manifestations of aberrant sleep in Fibromyalgia and related disorders include increased sleep latency, reduced sleep efficiency (Diaz-piedra et al., 2014), decreased REM latency, increased REM percent (Moldofsky, 2001; Riemann, 2007) and reduced deep sleep periods (Choy, 2015). Chronic impairments in sleep have thus been suggested to result in enhanced “allostatic load”-the increased energetic expenditure an organism is required to endure as a result of being forced to adapt to adverse psychosocial or physical situations (McEwen, 2000, 2006; Sapolsky, 2007). This allostatic accumulation may lead to further neural, physiological and behavioral abnormalities, as well as subsequent pain facilitation, resulting in a vicious cycle

(Borsook et al., 2012). Accordingly, Fibromyalgia is considered a prototype of the "central sensitization syndrome"; hypersensitivity of the central nervous system that is assumed to underlie a spectrum of complex psychiatric and somatic conditions including: posttraumatic stress disorder (PTSD), migraine headache and premenstrual dysphoric disorder (Yunus, 2008, 2007). The common denominator of these disorders could be impaired homeostasis manifested in sleep disturbance and emotion dysregulation .

A key factor regulating both sleep and emotion is the amygdala (Goldstein-Piekarski et al., 2015; Wager et al., 2008). Indeed, Fibromyalgia patients display altered limbic functionality as indicated by neural activity and connectivity studies (Cifre et al., 2012; Dehghan et al., 2016; Jensen et al., 2012) as well as reductions in gray matter volume within the amygdala (Burgmer et al., 2009; Lutz et al., 2008). Interestingly, limbic abnormalities have also been demonstrated in sleep deprivation (Simon et al., 2015; Yoo et al., 2007) as well as in "central sensitization syndrome" disorders such as PTSD (Hendler et al., 2003; Shin et al., 2006). We therefore hypothesized that neuromodulation of limbic activity using NF would serve as a good target for patients suffering from Fibromyalgia.

Numerous studies have demonstrated that using real-time fMRI-NF, healthy individuals can successfully modulate their limbic activity and present behavioral changes related to the targeted brain probe (for review see Sitaram et al., 2017). Clinical studies have further demonstrated similar results using amygdala driven fMRI-NF across several homeostatic/central sensitization disorders **such as PTSD (Nicholson et al., 2017), borderline personality disorder (Paret et al., 2016) and major depression (Young et al., 2017a, 2017a)**.

In chronic pain, two studies examined the efficacy of rt-fMRI-NF by targeting the rACC (rostral Anterior Cingulate Cortex); a major node in the affect aspect of the pain matrix (deCharms et al., 2005; Guan et al., 2015). Results of these studies showed an improvement in ongoing pain following rt-fMRI-NF training, claiming an effect of rACC down regulation on pain perception. However, due to small sample sizes in both studies and at least in one study (i.e. deCharms et al., 2005), lack of replication and proper control (deCharms, 2012), the clinical benefit of NF for chronic pain should be supported by further evidence (Jensen et al., 2014).

Despite the potential of this treatment option, the high cost of real-time fMRI NF severely limits its use in community settings. Even when available, the number of training sessions for each individual ends up being restricted by equipment availability. Moreover, traditional criteria for MRI compatibility may result in the exclusion of a significant subset of patients. To overcome such difficulties, we recently introduced a novel approach that combines the advantages of fMRI and EEG, i.e., high anatomical resolution and widespread availability, respectively. **Our technology is based on an fMRI-driven EEG computational model, that reflects amygdala activation and supporting regulation networks (i.e. limbic and salience systems) as depicted in simultaneous EEG/fMRI recording, termed here "Amygdala-Electrical Fingerprint" (Amyg-EFP) (Keynan et al., 2016; Meir-Hasson et al., 2016, 2014)**. In a series of validation studies on a separate group of healthy participants, we have shown that NF training employing the Amyg-EFP signal as a probe, resulted in improved targeting of the amygdala BOLD (Blood-oxygen-level dependent) signal in a subsequent fMRI session (Keynan et al., 2016). **Feather**, **we have recently demonstrated that repeated session Amyg-EFP-NF resulted in improved emotion regulation as well as enhanced amygdala-BOLD down regulation and amygdala-vmPFC functional connectivity** (Keynan et al., Accepted)

Utilizing Amyg-EFP for the first time in the clinical domain we have now conducted a multisession, double-blind, placebo-controlled NF trial in patients suffering from Fibromyalgia. The goal was to train individuals to down-modulate the Amyg-EFP signal and to examine the training effect on chronic pain as well as on ancillary symptoms related to somatic and affective regulation. We obtained subjective assessment of pain, sleep and affect dysregulation, as well as objective measures of sleep quality. Of the numerous manifestations of aberrant sleep in Fibromyalgia, our focus was on REM latency, which is known to be related to amygdala activation (Luppi et al., 2004; Nofzinger et al., 2004) and affective dysregulation in mood disorders (Kupfer, 1976; Palagini et al., 2013).

We hypothesized that: (1) Fibromyalgia patients in the **Real-NF group** would exhibit greater down modulation of the Amyg-EFP signal than the control group. (2) Given that our training probe was limbic and not classically related to the core pain processing network (Apkarian et al., 2005), we expected that the **Amyg-EFP-NF** training would differentially improve ancillary symptoms related to **homeostasis** as demonstrated by sleep and affect impairments. Moreover, we expected these changes to be accompanied by improvement in chronic pain symptoms. (3) Individual differences in treatment outcome improvement would correspond to **Real-NF** success.

2. Materials and methods

2.1 Participants

Patients were recruited from the Fibromyalgia clinic of the Institute of Rheumatology and from the Institute of Pain Medicine at Tel Aviv Medical Center in Israel. All patients had a diagnosis of Fibromyalgia according to the American College of Rheumatology (ACR) 2010 criteria (Wolfe et al., 2011) which was confirmed by a clinical interview and physical examination by an expert rheumatologist or pain specialist. Exclusion criteria included other chronic pain syndromes, major neuropsychiatric illness and recently changed/initiated pharmacotherapy. Patients were randomly assigned using a computerized algorithm to either sham-EFP or true NF interventions, with an a-priori ratio of 1:2 favoring the latter. This ratio was determined in order to allow for subgrouping of the true intervention group into good and poor NF modulators. Blinding was performed using in-house computer software and a file containing participant's group affiliation was examined only when NF data collection had ended. Thus, participants, care providers and clinicians assessing outcomes were all blinded to treatment.

In total, 136 FM patients underwent initial screening during which ninety-three subjects were excluded: seventy-four did not wished to participate for various personal reasons and nineteen did not meet the ACR 2010 criteria. Forty-three participants underwent randomization and were allocated randomly to real or sham NF intervention. This resulted in 31 participants randomly allocated to the real NF group and 12 participants allocated to the sham group (in total n=43). Of the 31 participants that were allocated to the real NF group, 6 dropped out voluntarily, resulting in 25 participants (24 females) that underwent the full real Amyg-EFP NF treatment.Of the 12 participants allocated to the sham NF group, 3 dropped out voluntarily, resulting in 9 (7 females) participants that underwent the full sham NF treatment, totaling 34 FM patients who completed the main procedure (age=35.62±6.1, 31 females, 79% retention, see table 1).

2.2 General procedure

Treatment study: The study was conducted at the Sagol Brain Institute, Tel Aviv Sourasky Medical Center and was approved by the Institutional Ethical Review Board. All participants provided written informed consent before entering the study.
Prior to the NF treatment course, patients underwent a "pre-NF" (pre) assessment that included a clinical evaluation, disease-related questionnaires, and one night of home sleep monitoring using an ambulatory sleep device (WatchPAT-200; Itamar Medical). Patients then underwent ten biweekly sessions of either **Real-NF** or sham-EFP. After completing the NF course patients underwent "Post NF" (post) assessment, conducted within one week of the last NF session. This evaluation was identical to the baseline assessment (see Fig. 1).

Follow-up assessment: As part of a new study, **examining the feasibility of a new NF technique, we re-contacted subjects who participated in the study. We** were able to **reach** 32 subjects 16.2±8.72 months following completion of NF training (**Real-NF group**=23**, the two participants who did not complete follow-up were in the "good modulators" subgroup**, **for details regarding characteristics of this sample see Table S2)**. We used this opportunity for an exploratory assessment of long-term effects of the **Real-**Intervention using the same outcome questionnaires (see outcome measures). Notably, during the time of this follow up, subjects were still blinded to the type of treatment they received (**real** or sham- **NF**). Of note, all analyses of the follow-up assessment included time from the end of treatment as a covariant to account for variability across participants (see Statistical analysis). **Also at this time point, no marked difference in pharmacological treatment were observed between real NF and sham groups (see Table S2).**

2.3 Neurofeedback procedure

NF treatment course protocol included ten NF sessions, each **session was composed of training either using an auditory interface (sessions one, three and five), an animated scenario interface (sessions two, four and six) or both (sessions seven, eight nine and ten in the same order across sessions) (see Fig S1A).** Missing more than two NF sessions, out of a total of ten, was determined as a criterion for exclusion. Five participants from the **Real-NF group** missed two sessions.

Patients were trained to downregulate their Amyg-EFP using two interfaces for feedback: 1. An auditory interface in which the neural signal correlated with the volume of a soft piano tune (Kinreich et al., 2014), and 2. A 3D audio-visual animated scenario in which the neural signal is correlated with the level of unrest in a scenario where virtual characters in a waiting room become impatient, leave their seats and gesture loudly at the front desk receptionist (Cohen et al., 2016) **(for illustration see Fig S1B).The decision to use two different interfaces aimed to encourage broad exploration of mental strategies, which can potentially lead to better regulation abilities. As the advantage of multi-modal stimuli has been demonstrated in various contexts of perceptual learning (Gibson and Maunsell, 1997; Kriegstein and Giraud, 2006; Shams and Seitz, 2008) and were suggested to strengthen integrative processes (van Atteveldt et al., 2014), we decided to introduce participants to varied feedback environments that would potentially maximize their regulation performance.** Within each session, NF trials contained two conditions: rest and regulate. Participants were instructed to modulate the interface only during the regulate condition. The **Real-NF group** received feedback reflecting their Amyg-EFP signal level modulation while the control group received feedback reflecting a pre-recorded Amyg-EFP signal obtained from another successful participant in the **Real-NF group**, indicating approximately 85 percent success in each session. EFP signal for the sham NF condition was obtained from different participants in accordance with the relevant order of sessions and feedback modality. This method of producing a sham signal enabled us to **control for "NF general effects" such as *control* (applying mental strategies in the attempt to modulate the presented neural pattern), *reward* (valuation of positive/negative outcomes of applied strategies) and *Learning* (the consolidation of associations between reward feedback cues and neural activity patterns) (Sitaram et al., 2017).**

2.4 EEG acquisition and on-line calculation

EEG data was acquired using the V-Amp™ EEG amplifier (Brain Products™, Munich Germany) and the BrainCap™ electrode cap with sintered Ag/AgCI ring electrodes (Falk Minow Services™, Herrsching-Breitburnn, Germany). Electrodes were positioned according to the standard 10/20 system. The reference electrode was

between Fz and Cz. Raw EEG signal was sampled at 250 Hz and recorded using the Brain Vision Recorder™ software (Brain Products). Amyg-EFP amplitude was calculated based on data recorded from the Pz channel using an in-house algorithm (Meir-Hasson et al., 2016, 2014). See supplementary material for more details.

2.5 NF success measure

Similar to in previous studies (Cohen et al., 2016), success in Amyg-EFP signal downregulation was assessed by calculating a personal effect size (Cohen's *d*) of each subject in each trial using the following formula:

$$\text{Effect size}=\frac{\text{mean rest}-\text{mean regulate}}{\sqrt{(SD\,rest^2+\,SD\,regulate^{\,2})}}$$

As the neural target was Amyg-EFP down regulation, a desired result would be lower "regulate" than "rest" values, resulting in a bigger (more positive) effect size **(see Fig. S1C for a graphic description)**

Overall success (across all sessions) was evaluated using a *global NF score:* we first calculated z-scores for the effect size for each NF session for each interface. Using these z-scores, we then calculated the mean effect size across all sessions.

In order to assess the contribution of success in NF to changes in clinical status, we wished to cluster the real-NF group into two subgroups based on their performance. Clustering was based on relative difference within the real-NF group. To this end, we used the popular k-means algorithm that clustered the two subgroups based on effect sizes from all the sessions. This clustering was further validated by median split of the *global NF score,* resulting in two sub-groups: good (n=13**, 13 female) and** poor (n=12**, 11 female**) modulators. To assess the improvement in NF learning over sessions we calculated the delta between the normalized effect size in the first and last sessions in both interfaces. This was labeled the *NF learning index.*

2.6 Outcome Measures

Self-report measures: In order to assess the patient's condition in three core symptoms of Fibromyalgia (pain, sleep experience and affect) we used the following validated self-report questionnaires: Fibromyalgia impact questionnaire (FIQ)

(Burckhardt et al., 1991), trait anxiety inventory (STAI-T) (Spielberger et al., 1970), Beck depression inventory (BDI) (Beck et al., 1961), the Pittsburgh sleep quality index (PSIQ) (Buysse et al., 1989) and the McGill pain questionnaire (Melzack, 1975), which also includes a Visual Analogue Scale (VAS). To tackle the overlap evident across these questionnaires, three compound scores were computed from all subscales reflecting pain, sleep experience, and affect. The compound scores were based on reliability tests, indicating the overall consistency of a measure by representing the proportion of systematic variation in a scale. Each scale was constructed using the combination of self-report scales that provided the highest reliability score, measured using Cronbach's alpha (Cronbach, 1951; Tavakol and Dennick, 2011). *Affect* was assessed using mean normalized score of the STAI-T questionnaire, the BDI questionnaire, and the anxiety and depression subscales of the FIQ questionnaire (Cronbach's alpha =0.76). *Sleep experience* was assessed using normalized score of the PSIQ and the fatigue subscale of the FIQ questionnaire (Cronbach's alpha =0.77). *Pain* was assessed using VAS and general score of the McGill pain questionnaire and subscales of the FIQ for pain (Cronbach's alpha=0.91).

Sleep assessment: One-night sleep monitoring was performed up to one week before and after the NF training course using the WachPAT-200 device. This device is based on recordings of peripheral arterial tone, along with pulse rate, actigraphy, and pulse oximetry. The WachPAT-200 was shown to accurately detect sleep versus wakefulness (Hedner et al., 2004), to differentiate light and deep sleep, and to detect REM sleep (Bresler et al., 2008; Hedner et al., 2011; Herscovici et al., 2007).

REM latency **(i.e. time span between the start of sleeping and the start of the first REM episode)** was used as the main sleep outcome measure due to prior work demonstrating a robust link between increased REM latency and mood regulation disorders (Palagini et al., 2013). To assess sleep more globally, we created an index composed of several features **known to be** important for sleep in Fibromyalgia. **This index reflected** increased sleep latency **(time between going to bed and falling asleep**), reduced sleep efficiency **(the ratio of the total time spent asleep compared to the total amount of time spent in bed)** and lack of proper deep sleep **(quantified using "deep sleep percent" and "REM sleep percent", i.e. the ratio of the total time spent in deep/REM sleep out of the total sleep time)** (Spaeth et al., 2011). Each measure was **standardized and given** a positive or negative coefficient,

reflecting its **contribution** to the **sleep abnormality** in **Fibromyalgia**: sleep latency (-1), sleep efficiency (+1), REM latency (+1), deep sleep percent (+1) and REM sleep percent (-1). **The average of these weighted and standardized scores was defined as the *composite sleep score*.**

2.7 Statistical analyses

Analyses were performed using IBM SPSS, version 20, Statistica version 10 (StatSoft, Inc) and MATLAB 2013b. Demographic results were descriptive and expressed as mean±standard deviation (see table.1). We compared the baseline characteristics of each group using chi-square or Fisher's exact test for categorical variables, and two-sample t-test for continuous variables. All reported p values are two tailed and Bonferroni corrected (Dunn, 1961) with respect to the number of comparisons conducted in each analysis, unless stated otherwise.

Real-NF group

2.7.2 Outcome measures

To evaluate treatment effect, we used mainly repeated measures ANOVAs, with between-subject factor of group (Amyg-EFP-NF/sham-EFP). **To evaluate NF learning we used NF session (first/last) as within-subject factor and for clinical improvement we used pre/post NF training within-subject factor.**

To assess the contribution of NF regulation abilities to the clinical outcome, we categorized the Real-NF group into two subgroups according to their success (see above). We then performed repeated measures ANOVA with clinical outcome as dependent variable, with three groups (good modulators/poor modulators and sham-EFP) as between subject factor and time (pre/post NF) as the within subject factor.

When assessing clinical improvement at follow-up, a covariant of time from end of treatment was included in all statistical models. Treatment effects were tested at a two-sided significance level of 0.05. Change in outcome measures was quantified using effect size (Cohen's d) (Cohen, 1992, 1988).

For clinical efficacy assessment, we evaluated the number needed to treat (NNT) for our primary objective sleep outcome measure, REM latency, and for pain reduction. NNT represents the number of patients that need to be treated for one patient to

benefit compared with a control (Laupacis et al., 1988). Thus, higher NNT indicates less effective treatment (Cordell, 1999). For normalized sleep, we defined clinical improvement as a patient that had a pre-assessment REM latency of less than 90 minutes and post-NF assessment of more than 90 minutes. Reduced pain was defined as at least forty percent decrease in visual analog scale (VAS).

2.7.3 Moderation analysis

To examine whether reduction in pain ratings in the follow-up assessment was due to clinical changes observed at the end of the NF training, we used moderation analysis. This analysis determines whether the size of the effect of some putative causal variable X on outcome Y depends on a moderator variable (Hayes, A. F., 2013). In other words, how the interaction between two independent variables can contribute to the prediction of the outcome variable. Specifically, we applied this concept to examine whether changes in *composite sleep score* moderate the manner by which initial improvement in extra-musculoskeletal symptoms (i.e. *affect* and s*leep experience*) impact pain improvement in the long run. For this moderation analysis we used the bootstrap method of Preacher and Hayes (Preacher and Hayes, 2004), which enabled estimation of the effects that *composite sleep score* (pre-post), *affect* (pre-post), s*leep experience* (pre-post) and their interaction had on pain in the follow-up assessment (post-follow-up). This was done with time from the end of NF training as covariant. We evaluated the contribution of *composite sleep score* as moderator and of each predictor separately, based on 5000 bootstrap samples using SPSS macro version 3 (www.processmacro.org).

3. Results

3.1 Neurofeedback learning and success

In accordance with our first hypothesis, we found improved performance in **Amyg-EFP regulation abilities** in the last compared to the first training session **in the Real-NF**, but not in the control group (Fig. 2A). A repeated measures ANOVA revealed greater NF learning in the **Real-NF group** compared to the control group [Session*Group interaction F(*1*,*32*)=*9.7*; p<0.0*05*; **d=1.24**], with first-last session difference significant for the **Real-NF group** only [post hoc pBonferroni<0.0005].**(for further details regarding results of NF learning see supplementary material)**

We then sought to examine whether performance during the first NF sessions were predictive of overall NF regulation performance. To this end, a regression model was built using **Real-NF group data (n=25). The model's aim was to predict the average effect size of sessions 3-10 using the first two NF sessions. To this end, two predicting variables were entered into the model: the effect size of the first animated scenario session and the effect size of the first auditory session. The final model contained only the animated scenario success index as a single predictor, as its predictive power had a more significant contribution. The auditory success index did not contribute significantly to the model and was thus excluded from its final version. The final model accounted for 16.5% (adjusted R square) of the variance in the dependent variable; overall regulation performance [F(1,24)=5.6;p<.05] (see Fig. 2B)**

.

3.2 Neurofeedback training outcomes

Our second hypothesis asserted that **Real-NF** training would improve homeostatic indices such as sleep and affect as well as measures of pain **(for full details regarding clinical outcomes see supplementary table 1)**. **Notably, one participant from the Real-NF group was not included in this analysis, as he did not provide self-report measures in the pre-assessment.** Focusing first on subjective measures of *affect*, *sleep experience* and *pain* we did not find any significant effects of NF

treatment (all Time*Condition p>0.16). Following our a-priori assumption, we nevertheless tested for the simple effect of time in each group. This analysis revealed two significant results: *affect* was improved in the **Real-NF group** only, and *sleep experience* was improved across both groups (p<0.01; p<0.005 respectively) (Fig. 3A-C).

In contrast, analysis of the objective measures of sleep: REM latency and *composite sleep score* (see methods), indicated greater improvement in **real** than **sham-NF** group after treatment. [Time*Condition interaction; REM latency: F (1,30) =4.43; p<0.05; **d=0.85**, *composite sleep score*: F (1,30)=6.81; p<0.05;**d=1.05**]. The NNT calculation for normalizing REM latency to at least ninety minutes, was 3.875. **Of note**, two subjects were unable to perform one session of objective sleep assessment due to technical difficulties and were thus excluded from the analysis. **The two missing datasets belonged to participants from the Real-NF group; one from the good modulators and one from the poor modulators subgroup.**

3.3 Neurofeedback success relation to clinical outcome

Our third hypothesis predicted that individual differences in NF modulation would be reflected in clinical **Real-NF group outcome.** In contrast to our expectation, there was no significant Time*__Sub-group__ interaction for *affect*, *sleep experience* or pain (all p>0.18).

However, objective outcome measures confirmed our hypothesis for both REM latency [Time*Group, F(2,29)=4.46; p<0.05;**d=1.15**], and *composite sleep score* [Time*Group, F(2,29)=8.1; p<0.005; **d=1.4**], showing improvement over time only in good modulators [REM latency; pBonferroni<0.05, *composite sleep score*; pUncorrected<0.005]. We further computed a change index for REM latency and *composite sleep score* (the delta between the 'pre' and 'post' assessment) in order to confirm that improvement in objective sleep indices was greater in good modulators. We then used this index in a one-way ANOVA model. This test confirmed that good modulators improved to a greater degree compared to both the poor modulators or sham group [REM latency, good modulators vs. sham; pBonferroni<0.05, *composite sleep score*, good modulators vs. sham; pBonferroni<0.005, good modulators vs. poor modulators; pBonferroni<0.05] (Fig. 5A,B). The N**umber** N**eeded to** T**reat** per NF success subgroups for normalized REM latency, were 3.0 for good modulators and 6.5 for poor modulators.

3.4 Follow-up clinical outcome and their relation to immediate neurofeedback effect

To assess the long-term clinical impact of Amyg-EFP-NF treatment, we performed an unplanned assessment of self-report measurements 16.2±8.72 months following NF training, focusing on the subjective measures of *pain*, *affect* and *sleep experience*. We used a repeated measures ANOVA, with time (post-NF/follow-up) as within subject variable, condition (Amyg-EFP/Sham-EFP) as between subject variable and time elapsed since the end of the NF training as a covariant. This analysis demonstrated that *pain* and *sleep experience* were improved at follow-up relative to post-NF only in the **Real-NF group**, while *affect* showed a marginally significant effect (*pain:* Time*Condition [$F(1,28)=6.7$, $p<0.05$; **d=1.1**], ;post-hoc for time effect in **Real-NF group**, pBonferroni<0.05, *sleep experience:* Time*Condition [$F(1,28)=5.02$; $p<0.05$; **d=0.92**] ; post hoc-test for time effect in **Real-NF group**, pBonferroni<0.05, *affect:* Time* Condition [$F(1,28)=3.69$; $p=0.065$; **d=0.81**]) (Fig. 4A-C).

Lastly, to account for the relation between immediate clinical outcome following treatment and the long-term effect of pain reduction, we applied moderation analysis using a custom-made regression model (see methods). This analysis examined the manner by which immediate homeostasis related outcomes of *sleep experience*, *affect* and *composite sleep score* predict **long-term** pain reduction (Fig. 6). This analysis revealed **that** improvement in *composite sleep score* following NF training was predictive of *pain* reduction in the follow-up assessment [B=0.91; $p=0.01$; 95% CI (0.21, 1.6)]; **and that** the interaction between improvement in *composite sleep score* and subjective *affect* post NF training had an additional, significant contribution to **the** prediction of *pain* reduction at follow-up [B=1.9; $p<0.05$; 95% CI (0.19, 3.68)]. In contrast, self-reported *sleep experience* did not have any predictive power for long-term *pain* reduction and was not moderated by *objective sleep* score. Importantly, time elapsed from the end of NF training to follow-up assessment was used as a covariant and did not significantly contribute to the model. These results suggest that when both objective sleep and affective symptoms were improved initially, pain intensity in the follow-up assessment was improved to the greatest extent,

strengthening the idea that long-term pain alleviation relies on improvements in homeostatic indices.

4. Discussion

The goal of the current study was to utilize a disease-relevant fMRI-based EEG-NF in a clinical population and to assess NF training effects on somatic-affective homeostasis measures such as sleep quality, subjective affect and chronic-pain. To this aim, we applied **in a randomized placebo control manner ten** sessions of **Amyg-EFP-NF** (or sham-**NF**) in a cohort of Fibromyalgia patients. We were able to demonstrate **improved NF regulation abilities in the real NF group, followed by** a robust immediate improvement in objective measures of sleep quality (NNT for normalized REM latency was 3.87). Immediately after NF training, we found no improvement in chronic pain. However, exploratory long-term follow-up conducted 16.2±8.72 months after the completion of the NF course revealed delayed improvement in chronic pain and sleep experience when compared to the end of treatment. Importantly, pain improvement at follow-up could be predicted by improvement in objective sleep observed immediately after NF training and its interaction with improved affective symptoms.

We have previously shown that healthy individuals can learn to down modulate the Amyg-EFP signal after short NF training and that this modulation corresponds to altered BOLD activity of the amygdala (Keynan et al., 2016). More so, in a recent paper we demonstrate that repeated session of Amyg-EFP-NF result in improved neural as well as behavioral indices of emotion regulation (Keynan et al., Accepted)**. Here, we elaborate this concept by demonstrating that Fibromyalgia patients are also able to down modulate their Amyg-EFP signal via repeated NF sessions, thus proving the relevance of our novel imaging approach to limbic neuromodulation in a clinical set-up.**

Markedly, when comparing pre-intervention to follow-up assessment, NNT for 40% reduction in pain intensity (measured using visual analog scale) was 3.14. **This result indicates relatively high clinical effectiveness, in comparison to common treatment medication; e.g.** Milnacipran **was reported to have** NNT **of** 8.5 (Cording et al., 2015), Duloxetine 7.2, and Pregabalin 8.6 (Bellato et al., 2012). As current treatment guidelines for chronic pain in general, and Fibromyalgia in particular,

emphasize the value of multimodal interventions (Häuser et al., 2015; Nüesch et al., 2013) these results seems to carry high **clinical** relevance.

4.1 Limbic function and chronic pain

In contrast with previous NF studies in the setting of chronic pain (deCharms et al., 2005; Guan et al., 2015), we employed a limbic probe for neuromodulation rather than targeting a traditional 'pain matrix' region (Apkarian et al., 2005). This decision was informed by accounts suggesting a critical role for the limbic system in chronic pain. Animal models demonstrated that amygdala hyperactivity generates enhanced feedforward inhibition of the medial prefrontal cortex, causing impaired cortical control that supports persistent activation of pain mechanisms (Neugebauer, 2015; Neugebauer et al., 2004). In humans, structural and functional limbic abnormalities predict transition from acute to chronic pain (Mansour et al., 2013; Vachon-Presseau et al., 2016). These findings support the idea that emotional states, underlined by limbic structures, may play a crucial role not only in pain perception and modulation, but also in its chronification (Baliki et al., 2012; Bushnell et al., 2013; Hashmi et al., 2013).

These propositions are nicely integrated in a recent theoretical framework which ascribes a main role for the limbic system in perceiving and maintaining bodily homeostasis; sensory information indicating the current state of the body is integrated in the limbic cortex and projected forward to construct an affect. According to this approach, aberrant perceptions regarding bodily states may hamper this process and can therefore cause chronic physical burdens, known as allostatic load, resulting in mental and physical illnesses such as depression (Barrett et al., 2016) and chronic pain (Di Lernia et al., 2016b). Guided by this conceptualization, we aimed to improve limbic modulation and therefore related homeostatic functions using Amyg-EFP-NF. **Indeed, our results suggest that improved limbic regulation resulted in distinct clinical improvement in sleep that later manifested in long-term pain relief (see Fig. 6)**

4.2 Sleep as a mediator in pain treatment

Sleep abnormalities are among the most common complaints in chronic pain in general, and are a major extra-musculoskeletal symptom in Fibromyalgia specifically

(Häuser et al., 2008; Yunus, 2007). Often more prominent than pain itself, sleep disorders have been suggested to be one of the main processes contributing to pain chronicity (Choy, 2015; Yunus, 2007). Accordingly, we found that improvement in objective indices of sleep immediately after the NF training predicted improvement in chronic pain during long term follow-up (Fig. 6). Moreover, we demonstrated that when both objective sleep and affective symptoms were improved at the end of the NF training, pain at **long term** follow-up was improved to the largest extent.

These results are in line with prior evidence that effective pharmacological and nonpharmacological therapies often improve both sleep quality and pain severity in Fibromyalgia patients. Treatment with sodium oxybate, a sleep modifier used to treat narcolepsy, led to improved pain ratings, correlated with decreased sleep disturbance (Moldofsky et al., 2010; Russell et al., 2009b; Spaeth et al., 2012). Likewise, pregabalin, an FDA approved medication for Fibromyalgia also has a beneficial effect on sleep (Mease et al., 2008; Russell et al., 2009a). Interestingly, some evidence suggests a positive effect for melatonin, commonly used for sleep aid to support pain relief in Fibromyalgia (de Zanette et al., 2014; Hussain et al., 2011; Reiter et al., 2007). Further, cognitive behavioral therapy was shown to improve subjective sleep as well as pain catastrophizing, anxiety and depression (Martínez et al., 2014).

Taken together, these findings support the suggestion that sleep may mediate the association between emotional symptoms and pain via amygdala functionality; It is well established that affective disorders such as anxiety and depression are highly comorbid with sleep dysregulation (Alvaro et al., 2013; Pires et al., 2016; Tsuno et al., 2005). Therefore, it was suggested that impaired sleep triggers unregulated aversive emotional processing by hampering affect reactivity and emotion regulation (Anderson and Platten, 2011; Krause et al., 2017; Minkel et al., 2012). Importantly, a key role is attributed to amygdala dysregulation in this maladaptive emotional processing, manly via impaired connectivity with the pre-frontal cortex (Goldstein and Walker, 2014; Motomura et al., 2013; Prather et al., 2013; Simon et al., 2015; Yoo et al., 2007). Moreover, the amygdala, together with the anterior cingulate cortex and anterior insula, forms the salience-detection network that mediates discrimination between stimuli of different emotional strengths. Following insufficient sleep this network displays non-specific, over generalizing responses to emotional cues (Goldstein and Walker, 2014). Importantly, structural and functional alterations in brain regions of the salience and emotional arousal networks are consistently evident

in patients with chronic visceral pain (Mayer et al., 2015), leading to the claim that chronic pain can be considered, at least in part, as a condition of altered responsive salience (Borsook et al., 2013). Disordered sleep has also been indicated as exacerbating pain chronicity by interfering with normal processing of interoceptive information; enabling awareness to our body state (Craig, 2003; Ewing et al., 2017). Indeed, a recent paper with Fibromyalgia patients demonstrated that objective sleep measures mediate the relation between pain intensity and level of anxiety and depression (Diaz-piedra et al., 2014). Altogether, our results support the idea that improvements in sleep may have a beneficial effect on chronic pain by restoring control mechanisms of homeostasis, which in turn breaks the vicious cycle of chronic pain, sleep disturbance and mood abnormalities (Choy, 2015).

4.3 Clinical perspective of Amyg-EFP-NF

The demonstration that a low-cost mechanism-based EEG-NF treatment can be clinically valuable in Fibromyalgia patients carries significant hope for this poorly managed syndrome. As expected, not all patients exhibited the same learning capacity. Previous reports have linked differences in NF performance to behavioral/clinical improvement (Kim et al., 2015; Wen et al., 2013; Zuberer et al., 2015), affirming the basic assumption that NF trains neural regulation, which alters behavior and improves clinical outcome (Thibault et al., 2017). **Here too, we observed that participants that presented enhanced Amyg-EFP regulation skills also displayed a more robust sleep related clinical improvement at the end of the NF training.**

Results from the full NF protocol analysis (see Fig. S.1) indicted that some participants in the Real-NF group were unable to regulate their Amyg-EFP signal better than sham-group participants. This result corresponds to previous findings suggested that a significant percent of the population (10-50%) are unable to influence their brain activity (Alkoby et al., 2017; Allison and Neuper, 2010; Jeunet et al., 2016). In previous studies, NF treatment efficiency was successfully predicted using behavioral factors such as control belief (Witte et al., 2013), motivation, mood (Nijboer et al., 2010, 2008), memory (Daum et al., 1993; Roberts et al., 1989; Wangler et al., 2011) or by EEG markers such as

resting-state alpha (Wan et al., 2014) or beta (Nan et al., 2015) (for detailed review see Alkoby et al., 2017). However, in our sample prediction was unsuccessful using behavioral, neural or clinical factors. Nonetheless, and as has been previously demonstrated (Neumann and Birbaumer, 2003; Weber et al., 2011), the first NF session, in this case, of animated scenario, was predictive for the overall NF regulation abilities (see Fig. 2B). We suggest that this quality might be due to the more enjoyable, engaging and relatable nature of the animated scenario interface (Cohen et al., 2016) as well as its multi-modality. As this interface was deliberately designed to provoke limbic activity and user engagement, we were pleased to observe that it could effectively predict treatment success.

Importantly, the pattern of clinical change observed here taps into the important issues of NF's latent effect (see Fig. 5). This subject was the focus of a recent study by Rance et al (Rance et al., 2018) that reported, that in two clinical populations (OCD and Tourette Syndrome), symptoms kept improving up to 80 days from the end of the NF training. The authors point out that a similar pattern of results is evident in previous NF studies at the behavioral (Amano et al., 2016), clinical (Schnyer et al., 2015) and neural (e.g Harmelech et al., 2013, Robineau et al., 2017, Yuan., 2014) levels.

Two mechanisms are suggested to underlie these latent effects. The first is behavioral: much like other coping skills, such as those acquired by cognitive behavioral therapy, (also demonstrated to have a latent effect e.g. Carroll et al., 1994; Goldstein et al., 1989; Piacentini et al., 2011) NF can turn into a skill that is integrated into daily life. Hence, as time goes by, it is possible that trainees continue to practice the new skill they acquired and thus symptoms and neural regulation continue to improve. The second mechanism suggested relates to neural learning principles: over time, consolidation and reconsolidation processes that underlie learning paradigms such as NF are likely to take place (Kandel et al., 2014). As these processes occur regardless of practice, synchronization, or desynchronization of the targeted brain process may increase over time (Rance et al., 2018).

The results we report here are consistent with Rance's et al suggestion regarding the latent effect of NF. However, our results concern a longer time duration than reported in previous papers and contains notable variance in sampling time.

Although we controlled for this variable in the relevant analyses by employing it as a covariate, ideally this should be factored in prospectively.

Our results also relate to the current discussion regarding the strong placebo effect of NF intervention (Thibault and Raz, 2017). A recent study that significantly contributed to this discussion, conducted by Schabus et al, used a full-length, widely accepted, EEG-NF protocol (increasing 12–15 Hz rhythm over the sensorimotor cortex) to improve the clinical status of insomnia patients. Results of this study showed no advantage to NF-treatment over sham treatment (Schabus et al., 2017). Similarly, we observed non-differential effect in subjective reports at the end of the NF training. However, as we targeted a specific neural probe, we witnessed an immediate effect on *objective* sleep measures related to NF training success, as well as long term clinical improvement evident in the **Real-NF group** only.

Interestingly, although a connection between modulation success and clinical outcome was observed, we could not find a correlation between these two measures. This may echo the suggestion by Ramos-Murguialday et al. (2013), that the nature of the relation between NF learning and behavioral/clinical outcomes should not necessarily be a linear one. Learning to control NF may follow similar principles as the learning of motor skills. As such, patients may acquire these "skills" via NF training, which then become part of their behavioral repertoire. Accordingly, one would expect that the acquisition of the skill by itself, rather than the level of proficiency, has the crucial effect on clinical outcomes.

4.4 Methodological considerations

We acknowledge that certain aspects of this study could be improved and hope that further research will untangle aspects that remained unsolved. The first issue is NF learning: In a recent study we demonstrated that trainee were able to down-modulate their Amyg-EFP signal better than active control after four Amyg-EFP-NF session (see Keynan et al., Accepted, Fig. 3). However, in the current study, participants showed improved Amyg-EFP regulation only at the final sessions (see Fig. S1). This slow learning process might be a characteristic of

the unhealthy populations in this study (as was briefly discuss in Schabus et al., 2017) or, alternately, might be due to the combination of different feedback interfaces that introduced additional challenges. By interleaving two interfaces, we hoped to provide an engaging training set-up for repeated sessions. However, in fact, this NF protocol might have disturbed an effective learning. Further, the relation between NF regulation and clinical outcome could have been better accounted for using transfer trails, which was unfortunately unavailable. Moreover**,** to, **fully control for effects of NF-reward related process (Emmert et al., 2016; Sitaram et al., 2017) it would preferable to use complete matching of success rates between the sham to real NF. Likewise, we believe that further studies** may apply additional control groups regulating a different brain probe rather than sham-EFP. Such an approach could help support the claim that targeting a specific domain, as done using the Amyg-EFP, indeed produces specific and differential results. **Clearly, we hope that the results presented here will be replicated in a bigger sample size and include** more elaborate and quantifiable measures of pain such as quantitative sensory testing or central pain modulation, that could potentially better characterize a relation between pain modulation and NF learning. **Lastly, as mentioned, the Amyg-EFP signal represents neural activity in a network of regions, including limbic and salience related areas (Keynan et al., 2016). Recent results suggest that Amyg-EFP-NF lead to improved amygdala BOLD modulation and increased connectivity to the vmPFC** (Keynan et al., Accepted)**. With that, in order to fully account for the relation between amygdala regulation and improved clinical outcome, fMRI exams in future studies would be beneficial.**

5. Conclusions

Using a randomized, double-blind, placebo-controlled design with outcome measurements of homeostasis (sleep and affect) and pain, and accounting for measures of learning (good versus poor modulators), we show that Amyg-EFP-NF can serve as a **scalable** non-pharmacological, non–invasive treatment for individuals suffering from Fibromyalgia. By examining the therapeutic potential of limbic modulation in the specific case of Fibromyalgia, this study further serves to support

771 the clinical potential of mechanism-driven fMRI driven EEG-NF approaches that
772 target specific neural processes relevant to different disease states, thus promising to
773 be a highly accessible therapeutic tool, both in medical settings as well as in the
774 patient's home environment.
775

6. Acknowledgements

We thank Dr. Ricardo Tarrasch for many helpful comments regarding statistical analysis. Our thanks are also given to Ms. Ayam Greental and Ms. Libat Weizman for assisting with data collection. We would like to give our thanks to Dr. Christian Paret that assisted us with graphic illustration. Finally, we thank Mr. Avi Lougassi for his continued and valuable support.

7. Funding

This research was funded by the Israeli Ministry of Science, Technology and Space (Grant No. 3-11170), by the Kamin Program of the Israel Innovation Authority and by the Israeli Pain Association Research Grant.

8. Declaration of interest

Prof. Hendler and Prof. Intrator are inventors of related patent applications entitled "Method and system for use in monitoring neural activity in a subject's brain" (US20140148657 A1, WO2012104853 A3, EP2670299 A2). This does not alter the authors' adherence to neuroimage policies.

Mr. Goldway, Dr. Ablin, Mr. Lubin, Mr. Zamir, Mr. Keynan, Miss. Or-Borichev, Prof. Cavazza, Dr. Charles, Dr. Brill, Dr. Ben-Simon, and Dr. Sharon all reported no biomedical financial interests or potential conflicts of interest.

References

Alkoby, O., Abu-Rmileh, A., Shriki, O., Todder, D., 2017. Can we predict who will respond to neurofeedback? A review of the inefficacy problem and existing predictors for successful EEG neurofeedback learning. Neuroscience.

Allison, B.Z., Neuper, C., 2010. Could anyone use a BCI?, in: Brain-Computer Interfaces. Springer, pp. 35–54.

Alvaro, P.K., Roberts, R.M., Harris, J.K., 2013. A Systematic Review Assessing Bidirectionality between Sleep Disturbances, Anxiety, and Depression. Sleep 36, 1059–1068. https://doi.org/10.5665/sleep.2810

Amano, K., Shibata, K., Kawato, M., Sasaki, Y., Watanabe, T., 2016. Learning to Associate Orientation with Color in Early Visual Areas by Associative Decoded fMRI Neurofeedback. Curr. Biol. 26, 1861–1866. https://doi.org/10.1016/j.cub.2016.05.014

Anderson, C., Platten, C.R., 2011. Sleep deprivation lowers inhibition and enhances impulsivity to negative stimuli. Behav. Brain Res. 217, 463–466.

Apkarian, A.V., Bushnell, M.C., Treede, R.-D., Zubieta, J.-K., 2005. Human brain mechanisms of pain perception and regulation in health and disease. Eur. J. Pain 9, 463–484. https://doi.org/10.1016/j.ejpain.2004.11.001

Arns, M., Kenemans, J.L., 2014. Neurofeedback in ADHD and insomnia: Vigilance stabilization through sleep spindles and circadian networks. Neurosci. Biobehav. Rev., Applied Neuroscience: Models, methods, theories, reviews. A Society of Applied Neuroscience (SAN) special issue. 44, 183–194. https://doi.org/10.1016/j.neubiorev.2012.10.006

Baliki, M.N., Petre, B., Torbey, S., Herrmann, K.M., Huang, L., Schnitzer, T.J., Fields, H.L., Apkarian, A.V., 2012. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat. Neurosci. 15, 1117.

Barrett, L.F., Quigley, K.S., Hamilton, P., 2016. An active inference theory of allostasis and interoception in depression. Phil Trans R Soc B 371, 20160011. https://doi.org/10.1098/rstb.2016.0011

Barrett, L.F., Simmons, W.K., 2015. Interoceptive predictions in the brain. Nat. Rev. Neurosci. 16, 419–429. https://doi.org/10.1038/nrn3950

Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An Inventory for Measuring Depression. Arch. Gen. Psychiatry 4, 561–571. https://doi.org/10.1001/archpsyc.1961.01710120031004

Bellato, E., Marini, E., Castoldi, F., Barbasetti, N., Mattei, L., Bonasia, D.E., Blonna, D., 2012. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res. Treat. 2012, 426130. https://doi.org/10.1155/2012/426130

Bigatti, S.M., Hernandez, A.M., Cronan, T.A., Rand, K.L., 2008. Sleep disturbances in fibromyalgia syndrome: Relationship to pain and depression. Arthritis Care Res. 59, 961–967. https://doi.org/10.1002/art.23828

Blackburn-Munro, G., Blackburn-Munro, R.E., 2001. Chronic pain, chronic stress and depression: coincidence or consequence? J. Neuroendocrinol. 13, 1009–1023.

Borsook, D., Edwards, R., Elman, I., Becerra, L., Levine, J., 2013. Pain and analgesia: The value of salience circuits. Prog. Neurobiol. 104, 93–105. https://doi.org/10.1016/j.pneurobio.2013.02.003

Borsook, D., Maleki, N., Becerra, L., McEwen, B., 2012. Understanding Migraine through the Lens of Maladaptive Stress Responses: A Model Disease of

Allostatic Load. Neuron 73, 219–234. https://doi.org/10.1016/j.neuron.2012.01.001

Bresler, M., Sheffy, K., Pillar, G., Preiszler, M., Herscovici, S., 2008. Differentiating between light and deep sleep stages using an ambulatory device based on peripheral arterial tonometry. Physiol. Meas. 29, 571. https://doi.org/10.1088/0967-3334/29/5/004

Burckhardt, C.S., Clark, S.R., Bennett, R.M., others, 1991. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18, 728–733.

Burgmer, M., Gaubitz, M., Konrad, C., Wrenger, M., Hilgart, S., Heuft, G., Pfleiderer, B., 2009. Decreased Gray Matter Volumes in the Cingulo-Frontal Cortex and the Amygdala in Patients With Fibromyalgia. Psychosom. Med. 71, 566–573. https://doi.org/10.1097/PSY.0b013e3181a32da0

Bushnell, M.C., Čeko, M., Low, L.A., 2013. Cognitive and emotional control of pain and its disruption in chronic pain. Nat. Rev. Neurosci. 14, 502–511. https://doi.org/10.1038/nrn3516

Buysse, D.J., Reynolds, C.F., Monk, T.H., Berman, S.R., Kupfer, D.J., 1989. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 28, 193–213. https://doi.org/10.1016/0165-1781(89)90047-4

Caria, A., Sitaram, R., Veit, R., Begliomini, C., Birbaumer, N., 2010. Volitional Control of Anterior Insula Activity Modulates the Response to Aversive Stimuli. A Real-Time Functional Magnetic Resonance Imaging Study. Biol. Psychiatry, Stress, Neuroplasticity, and Posttraumatic Stress Disorder 68, 425–432. https://doi.org/10.1016/j.biopsych.2010.04.020

Carroll, K.M., Rounsaville, B.J., Gordon, L.T., Nich, C., Jatlow, P., Bisighini, R.M., Gawin, F.H., 1994. Psychotherapy and Pharmacotherapy for Ambulatory Cocaine Abusers. Arch. Gen. Psychiatry 51, 177–187. https://doi.org/10.1001/archpsyc.1994.03950030013002

Choy, E.H.S., 2015. The role of sleep in pain and fibromyalgia. Nat. Rev. Rheumatol. 11, 513–520. https://doi.org/10.1038/nrrheum.2015.56

Cifre, I., Sitges, C., Fraiman, D., Muñoz, M.Á., Balenzuela, P., González-Roldán, A., Martínez-Jauand, M., Birbaumer, N., Chialvo, D.R., Montoya, P., 2012. Disrupted Functional Connectivity of the Pain Network in Fibromyalgia. Psychosom. Med. 74, 55–62. https://doi.org/10.1097/PSY.0b013e3182408f04

Cohen, A., Keynan, J.N., Jackont, G., Green, N., Rashap, I., Shani, O., Charles, F., Cavazza, M., Hendler, T., Raz, G., 2016. Multi-modal virtual scenario enhances neurofeedback learning. Front. Robot. AI 3, 52.

Cohen, J., 1992. A power primer. Psychol. Bull. 112, 155.

Cohen, J., 1988. Statistical power analysis for the behavioral sciences. 2nd. Hillsdale, NJ: erlbaum.

Cordell, W.H., 1999. Number Needed to Treat (NNT). Ann. Emerg. Med. 33, 433–436. https://doi.org/10.1016/S0196-0644(99)70308-2

Cording, M., Derry, S., Phillips, T., Moore, R.A., Wiffen, P.J., 2015. Milnacipran for pain in fibromyalgia in adults. Cochrane Libr.

Craig, A.D., 2003. Interoception: the sense of the physiological condition of the body. Curr. Opin. Neurobiol. 13, 500–505.

Cronbach, L.J., 1951. Coefficient alpha and the internal structure of tests. psychometrika 16, 297–334.

Daum, I., Rockstroh, B., Birbaumer, N., Elbert, T., Canavan, A., Lutzenberger, W., 1993. Behavioural treatment of slow cortical potentials in intractable epilepsy:

neuropsychological predictors of outcome. J. Neurol. Neurosurg. Psychiatry 56, 94–97. https://doi.org/10.1136/jnnp.56.1.94

de Zanette, S.A., Vercelino, R., Laste, G., Rozisky, J.R., Schwertner, A., Machado, C.B., Xavier, F., de Souza, I.C.C., Deitos, A., Torres, I.L., 2014. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol. Toxicol. 15, 40.

deCharms, R.C., 2012. 1st swiss rtfMRI neurofeedback conference.

deCharms, R.C., Maeda, F., Glover, G.H., Ludlow, D., Pauly, J.M., Soneji, D., Gabrieli, J.D.E., Mackey, S.C., 2005. Control over brain activation and pain learned by using real-time functional MRI. Proc. Natl. Acad. Sci. U. S. A. 102, 18626–18631. https://doi.org/10.1073/pnas.0505210102

Dehghan, M., Schmidt-Wilcke, T., Pfleiderer, B., Eickhoff, S.B., Petzke, F., Harris, R.E., Montoya, P., Burgmer, M., 2016. Coordinate-based (ALE) meta-analysis of brain activation in patients with fibromyalgia. Hum. Brain Mapp. 37, 1749–1758. https://doi.org/10.1002/hbm.23132

Di Lernia, D., Serino, S., Cipresso, P., Riva, G., 2016a. Ghosts in the machine. Interoceptive modeling for chronic pain treatment. Front. Neurosci. 10, 314.

Di Lernia, D., Serino, S., Riva, G., 2016b. Pain in the body. Altered interoception in chronic pain conditions: A systematic review. Neurosci. Biobehav. Rev. 71, 328–341. https://doi.org/10.1016/j.neubiorev.2016.09.015

Diaz-piedra, C., Catena, A., Miro, E., Martinez, M.P., Sanchez, A.I., Buela-casal, G., 2014. The Impact of Pain on Anxiety and Depression is Mediated by Objective and Subjective Sleep Characteristics in Fibromyalgia Patients. Clin. J. Pain 30, 852–859. https://doi.org/10.1097/AJP.0000000000000040

Dunn, O.J., 1961. Multiple comparisons among means. J. Am. Stat. Assoc. 56, 52–64.

Elman, I., Borsook, D., 2016. Common Brain Mechanisms of Chronic Pain and Addiction. Neuron 89, 11–36. https://doi.org/10.1016/j.neuron.2015.11.027

Emmert, K., Kopel, R., Sulzer, J., Brühl, A.B., Berman, B.D., Linden, D.E., Horovitz, S.G., Breimhorst, M., Caria, A., Frank, S., 2016. Meta-analysis of real-time fMRI neurofeedback studies using individual participant data: How is brain regulation mediated? Neuroimage 124, 806–812.

Ewing, D.L., Manassei, M., Gould van Praag, C., Philippides, A.O., Critchley, H.D., Garfinkel, S.N., 2017. Sleep and the heart: Interoceptive differences linked to poor experiential sleep quality in anxiety and depression. Biol. Psychol. 127, 163–172. https://doi.org/10.1016/j.biopsycho.2017.05.011

Gibson, J.R., Maunsell, J.H.R., 1997. Sensory Modality Specificity of Neural Activity Related to Memory in Visual Cortex. J. Neurophysiol. 78, 1263–1275. https://doi.org/10.1152/jn.1997.78.3.1263

Goldstein, A.N., Walker, M.P., 2014. The Role of Sleep in Emotional Brain Function. Annu. Rev. Clin. Psychol. 10, 679–708. https://doi.org/10.1146/annurev-clinpsy-032813-153716

Goldstein, M.G., Niaura, R., Follick, M.J., Abrams, D.B., 1989. Effects of Behavioral Skills Training and Schedule of Nicotine Gum Administation on Smoking Cessation. Am. J. Psychiatry 146, 56.

Goldstein-Piekarski, A.N., Greer, S.M., Saletin, J.M., Walker, M.P., 2015. Sleep Deprivation Impairs the Human Central and Peripheral Nervous System Discrimination of Social Threat. J. Neurosci. 35, 10135–10145. https://doi.org/10.1523/JNEUROSCI.5254-14.2015

946 Guan, M., Ma, L., Li, L., Yan, B., Zhao, L., Tong, L., Dou, S., Xia, L., Wang, M.,
947 Shi, D., 2015. Self-Regulation of Brain Activity in Patients with Postherpetic
948 Neuralgia: A Double-Blind Randomized Study Using Real-Time fMRI
949 Neurofeedback. PLOS ONE 10, e0123675.
950 https://doi.org/10.1371/journal.pone.0123675
951 Hamilton, N.A., Affleck, G., Tennen, H., Karlson, C., Luxton, D., Preacher, K.J.,
952 Templin, J.L., 2008. Fibromyalgia: The role of sleep in affect and in negative
953 event reactivity and recovery. Health Psychol. 27, 490–497.
954 https://doi.org/10.1037/0278-6133.27.4.490
955 Hashmi, J.A., Baliki, M.N., Huang, L., Baria, A.T., Torbey, S., Hermann, K.M.,
956 Schnitzer, T.J., Apkarian, A.V., 2013. Shape shifting pain: chronification of
957 back pain shifts brain representation from nociceptive to emotional circuits.
958 Brain 136, 2751–2768. https://doi.org/10.1093/brain/awt211
959 Hassett, A.L., Simonelli, L.E., Radvanski, D.C., Buyske, S., Savage, S.V., Sigal,
960 L.H., 2008. The relationship between affect balance style and clinical
961 outcomes in fibromyalgia. Arthritis Care Res. 59, 833–840.
962 https://doi.org/10.1002/art.23708
963 Häuser, W., Ablin, J., Fitzcharles, M.-A., Littlejohn, G., Luciano, J.V., Usui, C.,
964 Walitt, B., 2015. Fibromyalgia. Nat. Rev. Dis. Primer 1, nrdp201522.
965 https://doi.org/10.1038/nrdp.2015.22
966 Häuser, W., Zimmer, C., Felde, E., Köllner, V., 2008. [What are the key symptoms of
967 fibromyalgia? Results of a survey of the German Fibromyalgia Association].
968 Schmerz Berl. Ger. 22, 176–183. https://doi.org/10.1007/s00482-007-0602-z
969 Hayes, A. F., 2013. Introduction to Mediation, Moderation, and Conditional Process
970 Analysis: A Regression-Based Approach. Guilford Press.
971 Hedner, J., Pillar, G., Pittman, S.D., Zou, D., Grote, L., White, D.P., 2004. A Novel
972 Adaptive Wrist Actigraphy Algorithm for Sleep-Wake Assessment in Sleep
973 Apnea Patients. Sleep 27, 1560–1566. https://doi.org/10.1093/sleep/27.8.1560
974 Hedner, J., White, D.P., Malhotra, A., Herscovici, S., Pittman, S.D., Zou, D., Grote,
975 L., Pillar, G., 2011. Sleep Staging Based on Autonomic Signals: A Multi-
976 Center Validation Study. J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad.
977 Sleep Med. 7, 301–306. https://doi.org/10.5664/JCSM.1078
978 Hendler, T., Rotshtein, P., Yeshurun, Y., Weizmann, T., Kahn, I., Ben-Bashat, D.,
979 Malach, R., Bleich, A., 2003. Sensing the invisible: differential sensitivity of
980 visual cortex and amygdala to traumatic context. Neuroimage 19, 587–600.
981 Herscovici, S., Pe'er, A., Papyan, S., Lavie, P., 2007. Detecting REM sleep from the
982 finger: an automatic REM sleep algorithm based on peripheral arterial tone
983 (PAT) and actigraphy. Physiol. Meas. 28, 129. https://doi.org/10.1088/0967-
984 3334/28/2/002
985 Hussain, S.A.-R., Al-Khalifa, I.I., Jasim, N.A., Gorial, F.I., 2011. Adjuvant use of
986 melatonin for treatment of fibromyalgia. J. Pineal Res. 50, 267–271.
987 Jensen, K.B., Loitoile, R., Kosek, E., Petzke, F., Carville, S., Fransson, P., Marcus,
988 H., Williams, S.C., Choy, E., Mainguy, Y., Vitton, O., Gracely, R.H., Gollub,
989 R., Ingvar, M., Kong, J., 2012. Patients with fibromyalgia display less
990 functional connectivity in the brain's pain inhibitory network. Mol. Pain 8, 32.
991 https://doi.org/10.1186/1744-8069-8-32
992 Jensen, M.P., Day, M.A., Miró, J., 2014. Neuromodulatory treatments for chronic
993 pain: efficacy and mechanisms. Nat. Rev. Neurol. 10, 167–178.
994 https://doi.org/10.1038/nrneurol.2014.12

995 Jeunet, C., N'Kaoua, B., Lotte, F., 2016. Advances in user-training for mental-
996 imagery-based BCI control: Psychological and cognitive factors and their
997 neural correlates, in: Progress in Brain Research. Elsevier, pp. 3–35.
998 Kandel, E.R., Dudai, Y., Mayford, M.R., 2014. The Molecular and Systems Biology
999 of Memory. Cell 157, 163–186. https://doi.org/10.1016/j.cell.2014.03.001
1000 Keynan, J.N., Cohen, A., Jackont, G., Green, N., Goldway, N., Davidov, A., Meir-
1001 Hasson, Y., Raz, G., Intrator, N., Fruchter, E., Ginat, K., Laska, G., Cavazza,
1002 M., Hendler, T., Accepted. Amygdala Electrical Fingerprint-Neurofeedback
1003 During a Stressful Life Period Modifies Neurobehavioral Indices of Emotion
1004 Regulation. Nat. Hum. Behav.
1005 Keynan, J.N., Meir-Hasson, Y., Gilam, G., Cohen, A., Jackont, G., Kinreich, S., Ikar,
1006 L., Or-Borichev, A., Etkin, A., Gyurak, A., Klovatch, I., Intrator, N., Hendler,
1007 T., 2016. Limbic Activity Modulation Guided by Functional Magnetic
1008 Resonance Imaging–Inspired Electroencephalography Improves Implicit
1009 Emotion Regulation. Biol. Psychiatry, New Insight Into Depression
1010 Therapeutics 80, 490–496. https://doi.org/10.1016/j.biopsych.2015.12.024
1011 Kinreich, S., Podlipsky, I., Jamshy, S., Intrator, N., Hendler, T., 2014. Neural
1012 dynamics necessary and sufficient for transition into pre-sleep induced by
1013 EEG NeuroFeedback. NeuroImage 97, 19–28.
1014 https://doi.org/10.1016/j.neuroimage.2014.04.044
1015 Koush, Y., Meskaldji, D.-E., Pichon, S., Rey, G., Rieger, S.W., Linden, D.E.J., Van
1016 De Ville, D., Vuilleumier, P., Scharnowski, F., 2017. Learning Control Over
1017 Emotion Networks Through Connectivity-Based Neurofeedback. Cereb.
1018 Cortex 27, 1193–1202. https://doi.org/10.1093/cercor/bhv311
1019 Krause, A.J., Simon, E.B., Mander, B.A., Greer, S.M., Saletin, J.M., Goldstein-
1020 Piekarski, A.N., Walker, M.P., 2017. The sleep-deprived human brain. Nat.
1021 Rev. Neurosci. 18, 404–418. https://doi.org/10.1038/nrn.2017.55
1022 Kriegstein, K. von, Giraud, A.-L., 2006. Implicit Multisensory Associations Influence
1023 Voice Recognition. PLOS Biol. 4, e326.
1024 https://doi.org/10.1371/journal.pbio.0040326
1025 Kupfer, D.J., 1976. REM latency: a psychobiologic marker for primary depressive
1026 disease. Biol. Psychiatry 11, 159–174.
1027 Laupacis, A., Sackett, D.L., Roberts, R.S., 1988. An Assessment of Clinically Useful
1028 Measures of the Consequences of Treatment. N. Engl. J. Med. 318, 1728–
1029 1733. https://doi.org/10.1056/NEJM198806303182605
1030 Luppi, P.-H., Gervasoni, D., Boissard, R., Verret, L., Goutagny, R., Peyron, C.,
1031 Salvert, D., Leger, L., Barbagli, B., Fort, P., 2004. Brainstem structures
1032 responsible for paradoxical sleep onset and maintenance. Arch. Ital. Biol. 142,
1033 397–411. https://doi.org/10.4449/aib.v142i4.414
1034 Lutz, J., Jäger, L., de Quervain, D., Krauseneck, T., Padberg, F., Wichnalek, M.,
1035 Beyer, A., Stahl, R., Zirngibl, B., Morhard, D., Reiser, M., Schelling, G.,
1036 2008. White and gray matter abnormalities in the brain of patients with
1037 fibromyalgia: A diffusion-tensor and volumetric imaging study. Arthritis
1038 Rheum. 58, 3960–3969. https://doi.org/10.1002/art.24070
1039 Mansour, A.R., Baliki, M.N., Huang, L., Torbey, S., Herrmann, K.M., Schnitzer, T.J.,
1040 Apkarian, A.V., 2013. Brain white matter structural properties predict
1041 transition to chronic pain. PAIN® 154, 2160–2168.
1042 Martínez, M.P., Miró, E., Sánchez, A.I., Díaz-Piedra, C., Cáliz, R., Vlaeyen, J.W.S.,
1043 Buela-Casal, G., 2014. Cognitive-behavioral therapy for insomnia and sleep

hygiene in fibromyalgia: a randomized controlled trial. J. Behav. Med. 37, 683–697. https://doi.org/10.1007/s10865-013-9520-y

Mayer, E.A., Gupta, A., Kilpatrick, L.A., Hong, J.-Y., 2015. Imaging brain mechanisms in chronic visceral pain. Pain 156, S50.

McEwen, B.S., 2006. Sleep deprivation as a neurobiologic and physiologic stressor: allostasis and allostatic load. Metabolism, Sleep: Biological and Medical Perspectives 55, S20–S23. https://doi.org/10.1016/j.metabol.2006.07.008

McEwen, B.S., 2000. Allostasis and Allostatic Load: Implications for Neuropsychopharmacology. Neuropsychopharmacology 22, 108. https://doi.org/10.1016/S0893-133X(99)00129-3

Mease, P.J., Russell, I.J., Arnold, L.M., Florian, H., Young, J.P., Martin, S.A., Sharma, U., 2008. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J. Rheumatol. 35, 502–514.

Meir-Hasson, Y., Keynan, J.N., Kinreich, S., Jackont, G., Cohen, A., Podlipsky-Klovatch, I., Hendler, T., Intrator, N., 2016. One-Class FMRI-Inspired EEG Model for Self-Regulation Training. PLOS ONE 11, e0154968. https://doi.org/10.1371/journal.pone.0154968

Meir-Hasson, Y., Kinreich, S., Podlipsky, I., Hendler, T., Intrator, N., 2014. An EEG Finger-Print of fMRI deep regional activation. NeuroImage, Multimodal Data Fusion 102, 128–141. https://doi.org/10.1016/j.neuroimage.2013.11.004

Melzack, R., 1975. The McGill Pain Questionnaire: Major properties and scoring methods. PAIN 1, 277–299. https://doi.org/10.1016/0304-3959(75)90044-5

Minkel, J.D., Banks, S., Htaik, O., Moreta, M.C., Jones, C.W., McGlinchey, E.L., Simpson, N.S., Dinges, D.F., 2012. Sleep deprivation and stressors: evidence for elevated negative affect in response to mild stressors when sleep deprived. Emotion 12, 1015.

Moldofsky, H., 2001. Sleep and pain. Sleep Med. Rev. 5, 385–396. https://doi.org/10.1053/smrv.2001.0179

Moldofsky, H., Inhaber, N.H., Guinta, D.R., Alvarez-Horine, S.B., 2010. Effects of Sodium Oxybate on Sleep Physiology and Sleep/Wake-related Symptoms in Patients with Fibromyalgia Syndrome: A Double-blind, Randomized, Placebo-controlled Study. J. Rheumatol. 37, 2156–2166. https://doi.org/10.3899/jrheum.091041

Motomura, Y., Kitamura, S., Oba, K., Terasawa, Y., Enomoto, M., Katayose, Y., Hida, A., Moriguchi, Y., Higuchi, S., Mishima, K., 2013. Sleep debt elicits negative emotional reaction through diminished amygdala-anterior cingulate functional connectivity. PLoS One 8, e56578.

Nan, W., Wan, F., Vai, M.I., Da Rosa, A.C., 2015. Resting and Initial Beta Amplitudes Predict Learning Ability in Beta/Theta Ratio Neurofeedback Training in Healthy Young Adults. Front. Hum. Neurosci. 9. https://doi.org/10.3389/fnhum.2015.00677

Neely, R.M., Koralek, A.C., Athalye, V.R., Costa, R.M., Carmena, J.M., 2018. Volitional Modulation of Primary Visual Cortex Activity Requires the Basal Ganglia. Neuron. https://doi.org/10.1016/j.neuron.2018.01.051

Neugebauer, V., 2015. Amygdala pain mechanisms. Handb. Exp. Pharmacol. 227, 261–284. https://doi.org/10.1007/978-3-662-46450-2_13

Neugebauer, V., Li, W., Bird, G.C., Han, J.S., 2004. The Amygdala and Persistent Pain. The Neuroscientist 10, 221–234. https://doi.org/10.1177/1073858403261077

1094 Neumann, N., Birbaumer, N., 2003. Predictors of successful self control during brain-
1095 computer communication. J. Neurol. Neurosurg. Psychiatry 74, 1117–1121.
1096 https://doi.org/10.1136/jnnp.74.8.1117
1097 Nicholson, A.A., Rabellino, D., Densmore, M., Frewen, P.A., Paret, C., Kluetsch, R.,
1098 Schmahl, C., Théberge, J., Neufeld, R.W.J., McKinnon, M.C., Reiss, J., Jetly,
1099 R., Lanius, R.A., 2017. The neurobiology of emotion regulation in
1100 posttraumatic stress disorder: Amygdala downregulation via real-time fMRI
1101 neurofeedback. Hum. Brain Mapp. 38, 541–560.
1102 https://doi.org/10.1002/hbm.23402
1103 Nijboer, F., Birbaumer, N., Kubler, A., 2010. The Influence of Psychological State
1104 and Motivation on Brain–Computer Interface Performance in Patients with
1105 Amyotrophic Lateral Sclerosis – a Longitudinal Study. Front. Neurosci. 4.
1106 https://doi.org/10.3389/fnins.2010.00055
1107 Nijboer, F., Furdea, A., Gunst, I., Mellinger, J., McFarland, D.J., Birbaumer, N.,
1108 Kübler, A., 2008. An auditory brain–computer interface (BCI). J. Neurosci.
1109 Methods, Brain-Computer Interfaces (BCIs) 167, 43–50.
1110 https://doi.org/10.1016/j.jneumeth.2007.02.009
1111 Nijs, J., Loggia, M.L., Polli, A., Moens, M., Huysmans, E., Goudman, L., Meeus, M.,
1112 Vanderweeën, L., Ickmans, K., Clauw, D., 2017. Sleep disturbances and
1113 severe stress as glial activators: key targets for treating central sensitization in
1114 chronic pain patients? Expert Opin. Ther. Targets 21, 817–826.
1115 https://doi.org/10.1080/14728222.2017.1353603
1116 Nofzinger, E.A., Buysse, D.J., Germain, A., Carter, C., Luna, B., Price, J.C., Meltzer,
1117 C.C., Miewald, J.M., Reynolds, C.F., Kupfer, D.J., 2004. Increased Activation
1118 of Anterior Paralimbic and Executive Cortex FromWaking to Rapid Eye
1119 Movement Sleep in Depression. Arch. Gen. Psychiatry 61, 695–702.
1120 https://doi.org/10.1001/archpsyc.61.7.695
1121 Nüesch, E., Häuser, W., Bernardy, K., Barth, J., Jüni, P., 2013. Comparative efficacy
1122 of pharmacological and non-pharmacological interventions in fibromyalgia
1123 syndrome: network meta-analysis. Ann. Rheum. Dis. 72, 955–962.
1124 https://doi.org/10.1136/annrheumdis-2011-201249
1125 Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A., Riemann, D., 2013. REM
1126 sleep dysregulation in depression: State of the art. Sleep Med. Rev. 17, 377–
1127 390. https://doi.org/10.1016/j.smrv.2012.11.001
1128 Paret, C., Kluetsch, R., Zaehringer, J., Ruf, M., Demirakca, T., Bohus, M., Ende, G.,
1129 Schmahl, C., 2016. Alterations of amygdala-prefrontal connectivity with real-
1130 time fMRI neurofeedback in BPD patients. Soc. Cogn. Affect. Neurosci. 11,
1131 952–960. https://doi.org/10.1093/scan/nsw016
1132 Piacentini, J., Bergman, R.L., Chang, S., Langley, A., Peris, T., Wood, J.J.,
1133 McCracken, J., 2011. Controlled Comparison of Family Cognitive Behavioral
1134 Therapy and Psychoeducation/Relaxation Training for Child Obsessive-
1135 Compulsive Disorder. J. Am. Acad. Child Adolesc. Psychiatry 50, 1149–1161.
1136 https://doi.org/10.1016/j.jaac.2011.08.003
1137 Pires, G.N., Bezerra, A.G., Tufik, S., Andersen, M.L., 2016. Effects of acute sleep
1138 deprivation on state anxiety levels: a systematic review and meta-analysis.
1139 Sleep Med. 24, 109–118.
1140 Prather, A.A., Bogdan, R., Hariri, P.A.R., 2013. Impact of sleep quality on amygdala
1141 reactivity, negative affect, and perceived stress. Psychosom. Med. 75, 350.

1142 Preacher, K.J., Hayes, A.F., 2004. SPSS and SAS procedures for estimating indirect
1143 effects in simple mediation models. Behav. Res. Methods Instrum. Comput.
1144 36, 717–731. https://doi.org/10.3758/BF03206553
1145 Rance, M., Walsh, C., Sukhodolsky, D.G., Pittman, B., Qiu, M., Kichuk, S.A.,
1146 Wasylink, S., Koller, W.N., Bloch, M., Gruner, P., 2018. Time course of
1147 clinical change following neurofeedback. NeuroImage.
1148 Reiter, R.J., Acuna-Castroviejo, D., Tan, D., 2007. Melatonin therapy in fibromyalgia.
1149 Curr. Pain Headache Rep. 11, 339–342.
1150 Riemann, D., 2007. Insomnia and comorbid psychiatric disorders. Sleep Med., The
1151 Art of Good Sleep 8, S15–S20. https://doi.org/10.1016/S1389-9457(08)70004-
1152 2
1153 Roberts, L.E., Birbaumer, N., Rockstroh, B., Lutzenberger, W., Elbert, T., 1989. Self-
1154 Report During Feedback Regulation of Slow Cortical Potentials.
1155 Psychophysiology 26, 392–403. https://doi.org/10.1111/j.1469-
1156 8986.1989.tb01941.x
1157 Russell, I.J., Crofford, L.J., Leon, T., Cappelleri, J.C., Bushmakin, A.G., Whalen, E.,
1158 Barrett, J.A., Sadosky, A., 2009a. The effects of pregabalin on sleep
1159 disturbance symptoms among individuals with fibromyalgia syndrome. Sleep
1160 Med. 10, 604–610. https://doi.org/10.1016/j.sleep.2009.01.009
1161 Russell, I.J., Perkins, A.T., Michalek, J.E., Oxybate SXB-26 Fibromyalgia Syndrome
1162 Study Group, 2009b. Sodium oxybate relieves pain and improves function in
1163 fibromyalgia syndrome: A randomized, double-blind, placebo-controlled,
1164 multicenter clinical trial. Arthritis Rheum. 60, 299–309.
1165 https://doi.org/10.1002/art.24142
1166 Sapolsky, R.M., 2007. Stress, Stress-Related Disease, and Emotional Regulation., in:
1167 Handbook of Emotion Regulation. Guilford Press, New York, NY, US, pp.
1168 606–615.
1169 Schabus, M., Griessenberger, H., Gnjezda, M.-T., Heib, D.P.J., Wislowska, M.,
1170 Hoedlmoser, K., 2017. Better than sham? A double-blind placebo-controlled
1171 neurofeedback study in primary insomnia. Brain 140, 1041–1052.
1172 https://doi.org/10.1093/brain/awx011
1173 Schnyer, D.M., Beevers, C.G., deBettencourt, M.T., Sherman, S.M., Cohen, J.D.,
1174 Norman, K.A., Turk-Browne, N.B., 2015. Neurocognitive therapeutics: from
1175 concept to application in the treatment of negative attention bias. Biol. Mood
1176 Anxiety Disord. 5. https://doi.org/10.1186/s13587-015-0016-y
1177 Shams, L., Seitz, A.R., 2008. Benefits of multisensory learning. Trends Cogn. Sci. 12,
1178 411–417. https://doi.org/10.1016/j.tics.2008.07.006
1179 Sherwood, M.S., Kane, J.H., Weisend, M.P., Parker, J.G., 2016. Enhanced control of
1180 dorsolateral prefrontal cortex neurophysiology with real-time functional
1181 magnetic resonance imaging (rt-fMRI) neurofeedback training and working
1182 memory practice. NeuroImage 124, 214–223.
1183 https://doi.org/10.1016/j.neuroimage.2015.08.074
1184 Shin, L.M., Rauch, S.L., Pitman, R.K., 2006. Amygdala, medial prefrontal cortex, and
1185 hippocampal function in PTSD. Ann. N. Y. Acad. Sci. 1071, 67–79.
1186 Simon, E.B., Oren, N., Sharon, H., Kirschner, A., Goldway, N., Okon-Singer, H.,
1187 Tauman, R., Deweese, M.M., Keil, A., Hendler, T., 2015. Losing Neutrality:
1188 The Neural Basis of Impaired Emotional Control without Sleep. J. Neurosci.
1189 35, 13194–13205. https://doi.org/10.1523/JNEUROSCI.1314-15.2015

Sitaram, R., Ros, T., Stoeckel, L., Haller, S., Scharnowski, F., Lewis-Peacock, J., Weiskopf, N., Blefari, M.L., Rana, M., Oblak, E., 2017. Closed-loop brain training: the science of neurofeedback. Nat. Rev. Neurosci. 18, 86.

Smallwood, R.F., Laird, A.R., Ramage, A.E., Parkinson, A.L., Lewis, J., Clauw, D.J., Williams, D.A., Schmidt-Wilcke, T., Farrell, M.J., Eickhoff, S.B., 2013. Structural brain anomalies and chronic pain: a quantitative meta-analysis of gray matter volume. J. Pain 14, 663–675.

Spaeth, M., Bennett, R.M., Benson, B.A., Wang, Y.G., Lai, C., Choy, E.H., 2012. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann. Rheum. Dis. 71, 935–942. https://doi.org/10.1136/annrheumdis-2011-200418

Spaeth, M., Rizzi, M., Sarzi-Puttini, P., 2011. Fibromyalgia and Sleep. Best Pract. Res. Clin. Rheumatol., Generalised Musculoskeletal Problems 25, 227–239. https://doi.org/10.1016/j.berh.2011.03.004

Spielberger, C.D., Gorsuch, R.L., Lushene, R.E., 1970. Manual for the state-trait anxiety inventory.

Tavakol, M., Dennick, R., 2011. Making sense of Cronbach's alpha. Int. J. Med. Educ. 2, 53–55. https://doi.org/10.5116/ijme.4dfb.8dfd

Thibault, R.T., Lifshitz, M., Raz, A., 2016. The self-regulating brain and neurofeedback: Experimental science and clinical promise. Cortex, What's your poison? Neurobehavioural consequences of exposure to industrial, agricultural and environmental chemicals 74, 247–261. https://doi.org/10.1016/j.cortex.2015.10.024

Thibault, R.T., MacPherson, A., Lifshitz, M., Roth, R.R., Raz, A., 2017. Neurofeedback with fMRI: A critical systematic review. NeuroImage. https://doi.org/10.1016/j.neuroimage.2017.12.071

Thibault, R.T., Raz, A., 2017. The psychology of neurofeedback: Clinical intervention even if applied placebo. Am. Psychol. 72, 679.

Tsuno, N., Besset, A., Ritchie, K., 2005. Sleep and depression. J. Clin. Psychiatry.

Vachon-Presseau, E., Tétreault, P., Petre, B., Huang, L., Berger, S.E., Torbey, S., Baria, A.T., Mansour, A.R., Hashmi, J.A., Griffith, J.W., Comasco, E., Schnitzer, T.J., Baliki, M.N., Apkarian, A.V., 2016. Corticolimbic anatomical characteristics predetermine risk for chronic pain. Brain J. Neurol. 139, 1958–1970. https://doi.org/10.1093/brain/aww100

van Atteveldt, N., Murray, M.M., Thut, G., Schroeder, C.E., 2014. Multisensory integration: flexible use of general operations. Neuron 81, 1240–1253.

Wager, T.D., Davidson, M.L., Hughes, B.L., Lindquist, M.A., Ochsner, K.N., 2008. Prefrontal-Subcortical Pathways Mediating Successful Emotion Regulation. Neuron 59, 1037–1050. https://doi.org/10.1016/j.neuron.2008.09.006

Wan, F., Nan, W., Vai, M.I., Rosa, A., 2014. Resting alpha activity predicts learning ability in alpha neurofeedback. Front. Hum. Neurosci. 8. https://doi.org/10.3389/fnhum.2014.00500

Wangler, S., Gevensleben, H., Albrecht, B., Studer, P., Rothenberger, A., Moll, G.H., Heinrich, H., 2011. Neurofeedback in children with ADHD: Specific event-related potential findings of a randomized controlled trial. Clin. Neurophysiol. 122, 942–950. https://doi.org/10.1016/j.clinph.2010.06.036

Weber, E., Köberl, A., Frank, S., Doppelmayr, M., 2011. Predicting Successful Learning of SMR Neurofeedback in Healthy Participants: Methodological Considerations. Appl. Psychophysiol. Biofeedback 36, 37–45. https://doi.org/10.1007/s10484-010-9142-x

Witte, M., Kober, S.E., Ninaus, M., Neuper, C., Wood, G., 2013. Control beliefs can predict the ability to up-regulate sensorimotor rhythm during neurofeedback training. Front. Hum. Neurosci. 7. https://doi.org/10.3389/fnhum.2013.00478

Wolfe, F., Clauw, D.J., Fitzcharles, M.-A., Goldenberg, D.L., Häuser, W., Katz, R.S., Mease, P., Russell, A.S., Russell, I.J., Winfield, J.B., 2011. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J. Rheumatol. 38, 1113–1122. https://doi.org/10.3899/jrheum.100594

Yoo, S.-S., Gujar, N., Hu, P., Jolesz, F.A., Walker, M.P., 2007. The human emotional brain without sleep—a prefrontal amygdala disconnect. Curr. Biol. 17, R877–R878.

Young, K.D., Misaki, M., Harmer, C.J., Victor, T., Zotev, V., Phillips, R., Siegle, G.J., Drevets, W.C., Bodurka, J., 2017. Real-Time Functional Magnetic Resonance Imaging Amygdala Neurofeedback Changes Positive Information Processing in Major Depressive Disorder. Biol. Psychiatry, Information Processing Alterations in Depression 82, 578–586. https://doi.org/10.1016/j.biopsych.2017.03.013

Yunus, M.B., 2008. Central Sensitivity Syndromes: A New Paradigm and Group Nosology for Fibromyalgia and Overlapping Conditions, and the Related Issue of Disease versus Illness. Semin. Arthritis Rheum., FIBROMYALGIA-aPL-TNF SLE-CA IN RA 37, 339–352. https://doi.org/10.1016/j.semarthrit.2007.09.003

Yunus, M.B., 2007. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract. Res. Clin. Rheumatol., General Musculoskeletal Conditions 21, 481–497. https://doi.org/10.1016/j.berh.2007.03.006

1268 Figures



1269

1270 Fig.1, **Experimental design**

1271

	Amyg-EFP-NF M±S.D	**Sham-NF M±S.D**	**T/Fisher's Exact Test**	**P-value**
Gender	1M 24F	2M 7F		0.16
Age	35.5±12.6	35.9±10.6	0.08	0.93
Time from diagnosis (years)	4.3±4.1	4.1±4.4	0.12	0.9
SSRI/SNRI (%)	16	33.33		0.35
Gabapentinoids (%)	24	33.33		0.67
Cannabis (%)	20	22.22		1
Analgesics (%)	8	0		1
Miscellaneous (%)	12	11		1
Pain (VAS, McGill, FIQ pain)	2.73±0.9	2.88.73±1.1	0.41	0.68
Affect (STAI-T, BDI, FIQ anxiety, FIQ depression)	2.53±0.7	2.84±0.7	1.02	0.32
Sleep experience (PSQI, FIQ fatigue)	4.17±0.9	3.93±1.0	0.69	0.49
REM latency (min)	76.67±35.2	90.0±34.5	0.97	0.34
Composite Sleep Score (sleep latency, sleep efficiency, REM latency, Deep Sleep percent, REM sleep percent)	-0.09±0.43	0.13±0.28	1.4	0.17

Table.1, **Baseline characteristics of the sample**. VAS- visual analog scale, FIQ-Fibromyalgia Impact Questionnaire, BDI-Beck's Depression Inventory, STAI T-Trait Anxiety Inventory, PSQI- Pittsburgh Sleep Quality Index



Fig.2, **NF learning. a.** Effect size for NF learning index in the first and last training sessions (black and gray boxes, respectively), per group (Real-NF/sham-EFP), with box plot displaying significant interaction of Session*Condition and simple effect of session only for the **Real-NF group**, showing greater learning effect at the last session compared to the first. ***b.*** **Scatterplot of the relation between effect size in the first animated scenario session and the average learning effect size across all the other sessions (3-10), showing significant positive correlation (r=0.44, Rsqr=0.16, p<0.05), thus pointing to a predictive value of the first animated scenario session with regard to later NF success**. **p <0.005, ***$p <$ 0.0005. Bonferroni post hoc correction**. This analysis is based on data from 25 real NF group participants.**



Fig.3, **Change in self-report readouts, pre to post assessment. a.** *Pain* readout (VAS, McGill general score, FIQ pain) pre/post NF training. Bar graphs display no main effect of time, nor interaction of Time*Condition. **b**. *Affect* readout (STAI-T, BDI, FIQ anxiety, FIQ depression) pre/post NF training. Bar graphs show simple effect for time (pre/post NF) only for the **Real-NF group**, without Interaction of Time*Condition. **c**. *Sleep experience* readout (PSQI, FIQ fatigue) pre/post NF training. Bar graphs show simple effect for time (pre/post NF) for both groups, without Interaction of Time*Condition. Error bars represent SEM. *p < 0.05; **p < 0.005. Bonferroni post hoc corrections**. This analysis is based on data from 33 participants, 24 from the real NF group and 9 from the sham NF group.**



Fig.4, **Change in self-report readouts, post-NF to follow-up assessment a.** *Pain* readout, post NF/ follow-up. Bar graphs show Interaction of Time*Condition and simple effect for time (post NF/follow-up) only for the **Real-NF group**. **b.** *Affect* readout, post NF/ follow-up. Bar graphs show marginal Interaction of Time*Condition (p=0.065) but no simple effect for time (post NF/ follow-up). **c.** *Sleep experience* readout. Bar graphs show Interaction of Time*Condition and effect for time (post NF/ follow-up) only for the **Real-NF group**. Error bars represent SEM. *p <0.05; **p <0.005. Bonferroni post hoc corrections. Values are presented with covariate of time from end of the study at level of 15.8 months. **This analysis is based on data from 31 participants, 22 from the real NF group and 9 from the sham NF group.**



Fig.5, **Objective sleep changes over time.** Difference between post and pre-NF, per subgroup (good modulators/poor modulators/sham) ***a.*** REM latency. Box plot displaying significant effect for group. Post hoc tests show significant difference between good modulators and sham. ***b.*** Composite Sleep Score (see methods). Box plot displaying significant effect for group. Post hoc tests show significant difference between good modulators and sham and between good and poor modulators. *$p < 0.05$; **$p < 0.005$. Bonferroni post hoc corrections. **This analysis is based on data from 32 participants, 22 from the real NF group and 9 from the sham NF group.**



1339

1340 Fig.6, **Pain improvement in follow-up session:** moderation analysis of follow-up
1341 pain improvement. **a.** Conceptual Diagram: the moderation model was designed to
1342 examine how objective sleep improvement, reflected by Composite Sleep Score (see
1343 methods), predicts long-term pain reduction and how this index moderates the
1344 contribution of *affect* and *Sleep experience* on this pain alleviation. **b.** Statistical
1345 illustration of the moderation. **This analysis is based on data from 30 participants,**
1346 **21 from the real NF group and 9 from the sham NF group.**

1347